Medicine and Dentistry
Chronic Kidney Disease
100%
Polycystic Kidney Disease
96%
Albuminuria
65%
Glomerular Filtration Rate
64%
Kidney Function
57%
Urinary System
49%
Nephropathy
45%
Population
42%
Cardiovascular System
39%
Creatinine
31%
Cardiovascular Disease
29%
Disease
28%
Kidney Graft
27%
Hazard Ratio
27%
Maturity Onset Diabetes of the Young
27%
Meta-Analysis
26%
Disease Exacerbation
23%
Cardiovascular Risk
23%
COVID-19
23%
Biological Marker
20%
Copeptin
20%
Diabetes
19%
Heart Failure
19%
Terminal Illness
19%
Tolvaptan
18%
End Stage Renal Disease
16%
Blood Pressure
14%
Renal Replacement Therapy
14%
Proteinuria
14%
Cohort Analysis
13%
Placebo
13%
Diabetes Mellitus
13%
Renal Failure
11%
Vasopressin
11%
Microalbuminuria
11%
High Density Lipoprotein Cholesterol
11%
Clinical Trial
10%
Body Mass Index
10%
Hemodialysis
10%
Post-Hoc Analysis
9%
C Reactive Protein
8%
Urine Sampling
8%
Nephrology
8%
Diabetic Nephropathy
8%
Prevalence
8%
Liver Polycystic Disease
8%
Disease Severity
8%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Potassium Excretion
7%
Heart Failure with Reduced Ejection Fraction
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
72%
Kidney Polycystic Disease
59%
Albuminuria
50%
Creatinine
40%
Cardiovascular Disease
37%
Disease
37%
Kidney Disease
32%
Tolvaptan
27%
Non Insulin Dependent Diabetes Mellitus
26%
Heart Failure
26%
Terminal Illness
25%
Cardiovascular Risk
24%
All Cause Mortality
20%
Placebo
20%
Biological Marker
20%
Copeptin
19%
Cohort Study
18%
Diabetic Nephropathy
16%
Kidney Failure
15%
Disease Exacerbation
14%
Vasopressin
14%
End Stage Renal Disease
14%
C Reactive Protein
14%
Diabetes Mellitus
13%
Cardiovascular Mortality
12%
Dipeptidyl Carboxypeptidase Inhibitor
12%
Clinical Trial
12%
Prevalence
11%
Receptor Antagonist
10%
Proteinuria
10%
Microalbuminuria
10%
Vasopressin V2 Receptor
9%
Antihypertensive Agent
9%
Venous Thromboembolism
9%
Coronavirinae
9%
Replacement Therapy
9%
Renin
8%
Disease Marker
8%
Brain Natriuretic Peptide
8%
Prospective Cohort Study
8%
Cystatin C
8%
Losartan
7%
Angiotensin Receptor Antagonist
7%
Randomized Clinical Trial
7%
Inflammation
6%
Metabolic Syndrome X
6%
Hemodialysis
6%
Insulin Resistance
6%
Prospective Study
6%
Angiotensin
6%
Keyphrases
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
53%
Albuminuria
50%
Chronic Kidney Disease
48%
Estimated Glomerular Filtration Rate
35%
Hazard Ratio
19%
Confidence Interval
18%
End-organ Disease
18%
Cardiovascular Risk
18%
Albumin-to-creatinine Ratio
17%
Urinary Albumin Excretion
17%
All-cause Mortality
16%
Hypertension
15%
Cardiovascular Disease
15%
Cardiovascular Events
14%
Cardiovascular Mortality
14%
Kidney Function
14%
COVID-19
14%
Copeptin
13%
Meta-analysis
13%
Risk Factors
13%
Disease Progression
12%
Tolvaptan
12%
Type 2 Diabetes Mellitus (T2DM)
11%
Total Kidney Volume
11%
Kidney Disease Progression
10%
Renal Function
10%
Kidney Disease
10%
Diabetes
10%
Diabetic Kidney Disease
10%
Heart Failure
9%
Proteinuria
9%
Placebo
9%
Egfr
9%
Cardiovascular Outcomes
9%
Prospective Cohort Study
8%
Dialysis
8%
Kidney Transplant Recipients
8%
Polycystic Kidney Disease
8%
Body Mass Index
8%
Type 2 Diabetic Patients
8%
High Risk
8%
Nephrology
8%
Glomerular Filtration Rate
8%
Kidney
8%
Microalbuminuria
7%
Adjusted Hazard Ratio
7%
Vasopressin
7%
Population-based Cohort
7%
Renal Disease
7%
Randomized Clinical Trial
7%
